ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

international apex pharmaceuticals inc.; distributor: international apex pharmaceuticals inc. - nicardipine hydrochloride - solution for injection (iv) - 1mg/ml (2mg/2ml)

ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

international apex pharmaceuticals, inc.; distributor: international apex pharmaceuticals, inc. - methotrexate - solution for injection (i.m./i.v.) - 25 mg/ml (50 mg/2ml)

ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

international apex pharmaceuticals, inc.; distributor: international apex pharmaceuticals, inc. - levofloxacin (as hemihydrate) - solution for iv infusion - 5mg/ml (750mg/150ml)

ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

international apex pharmaceuticals, inc. - clopidogrel (as bisulfate) - tablet, film coated - 75mg

ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

international apex pharmaceuticals, inc. - co-amoxiclav - tablet, film coated - 875mg + 125mg

ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

international apex pharmaceuticals, inc. - enoxaparin sodium - solution for injection (sc) - 60mg / 0.6ml

ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

international apex pharmaceuticals, inc. - heparin sodium - solution for injection (iv/sc) - 1+000 i.u. / ml

ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

international apex pharmaceuticals, inc. - meropenem - powder for injection (iv) - 500mg

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine delayed-release capsules are indicated for the treatment of: starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)] . pregnancy category c risk summary — there are no adequate and well-controlled studies of duloxetine administration in pregnant women. in animal studies with duloxetine, fetal weights were decreased but there was no evidence of teratogenicity in pregnant rats and rabbits at oral doses administered during the period of organogenesis up to 4 and 7 times the maximum recommended human dose (mrhd) of 120 mg/day, respectively. when duloxetine was administered orally to pregnant rats throughout gestation and lactation, pup weights at birth and pup survival to 1 day postpartum were decreased at a dose 2 times the mrhd. at this dose, pup behaviors consistent with i

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - duloxetine delayed-release capsules are indicated for the treatment of major depressive disorder (mdd). the efficacy of duloxetine was established in four short term and one maintenance trial in adults [see clinical studies (14.1) ]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. duloxetine delayed-release capsules are indicated for the treatment of generalized anxiety disorder (gad). the efficacy of duloxetine was established in three short-term trials and one maintenance trial in adults [see clinical studies